Remove 2007 Remove Epilepsy Remove Patients Remove Topical
article thumbnail

Rationale for Genetically Guided Cannabis Therapy

Green Relief

I was first introduced to the topic of Epigenetics in 2008 at a business conference in Florida, and as a medical professional I was immediately intrigued. Using genetic information to formulate a unique cannabis blend can decrease the “trial and error” phase upon starting cannabis, and provide more consistency in improving patient outcomes.

Therapy 40
article thumbnail

Perfecting cannabis with Michael Backes

The Cannigma

I was going to live at a place he was buying an Eagle Rock and this guy from Berkeley came in, Don Duncan, who had helped start Berkeley Patients Group and was going to open up LAPCG in Los Angeles. They bought it from your dispensary in Eagle Rock in 2007, and it’s still in their nightstand. I think that’s great advice.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ).

article thumbnail

The Endocannabinoid System: Here’s How it Keeps You Healthy and Happy

Greencamp

Because this is such a complicated topic, wrapping your head around everything requires some patience and dedication. Let’s check out the most notable aspects of this topic, which we’ll cover in great depth, one at a time. This is why CBD works wonders for anxiety ( 4 ) and also PTSD patients. Depression. Concussions.

article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.